SLAMF7 Restrains Pro-Inflammatory Macrophage Activation to Counteract Doxorubicin-Induced Cardiotoxicity

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-08-01 DOI:10.1016/j.jacbts.2025.02.015

Ao Liu MD, PhD , Peiyuan Bai MD, PhD , Hongmin You MD , Zehao Zhuang MD , Fangyan Tian MD, PhD , Haobo Weng MD, PhD , Xuemei Wei MD , Lu Tang MD , Litao Wang MD, PhD , Chaobao Liu MD , Jinghong Zhang MD , Minmin Sun MD, PhD , Shuning Zhang MD, PhD , Xianhong Shu MD, PhD , Junbo Ge MD, PhD

{"title":"SLAMF7 Restrains Pro-Inflammatory Macrophage Activation to Counteract Doxorubicin-Induced Cardiotoxicity","authors":"Ao Liu MD, PhD , Peiyuan Bai MD, PhD , Hongmin You MD , Zehao Zhuang MD , Fangyan Tian MD, PhD , Haobo Weng MD, PhD , Xuemei Wei MD , Lu Tang MD , Litao Wang MD, PhD , Chaobao Liu MD , Jinghong Zhang MD , Minmin Sun MD, PhD , Shuning Zhang MD, PhD , Xianhong Shu MD, PhD , Junbo Ge MD, PhD","doi":"10.1016/j.jacbts.2025.02.015","DOIUrl":null,"url":null,"abstract":"<div><div>Doxorubicin-induced cardiotoxicity (DIC) poses a significant challenge in cancer treatment. This study investigated the role of SLAMF7 in DIC, particularly in macrophage-mediated inflammation. Using SLAMF7 knockout mice, we found that SLAMF7 deficiency exacerbates DIC and amplifies inflammatory responses. Mechanistically, SLAMF7 interacts with TNF receptor-associated factor 6 to attenuate nuclear factor κB signaling, reducing oxidative stress and proinflammatory cytokines. Notably, administering recombinant SLAMF7 protein effectively mitigated DIC. These findings underscore the critical role of SLAMF7 in protecting against DIC, positioning it as a promising therapeutic target.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 8","pages":"Article 101256"},"PeriodicalIF":8.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25000737","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Doxorubicin-induced cardiotoxicity (DIC) poses a significant challenge in cancer treatment. This study investigated the role of SLAMF7 in DIC, particularly in macrophage-mediated inflammation. Using SLAMF7 knockout mice, we found that SLAMF7 deficiency exacerbates DIC and amplifies inflammatory responses. Mechanistically, SLAMF7 interacts with TNF receptor-associated factor 6 to attenuate nuclear factor κB signaling, reducing oxidative stress and proinflammatory cytokines. Notably, administering recombinant SLAMF7 protein effectively mitigated DIC. These findings underscore the critical role of SLAMF7 in protecting against DIC, positioning it as a promising therapeutic target.

查看原文本刊更多论文

SLAMF7抑制促炎巨噬细胞活化以对抗阿霉素诱导的心脏毒性。

阿霉素诱导的心脏毒性（DIC）对癌症治疗提出了重大挑战。本研究探讨了SLAMF7在DIC中的作用，特别是在巨噬细胞介导的炎症中。使用SLAMF7敲除小鼠，我们发现SLAMF7缺乏会加剧DIC并放大炎症反应。在机制上，SLAMF7与TNF受体相关因子6相互作用，减弱核因子κB信号，减少氧化应激和促炎细胞因子。值得注意的是，给药重组SLAMF7蛋白可有效缓解DIC。这些发现强调了SLAMF7在预防DIC中的关键作用，将其定位为一个有希望的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.